AusPAR Attachment 1: Product Information for Otezla

In Study PALACE 1, the proportion of patients with an ACR 20 response at Week 16 with concomitant DMARD use was 33.0 % for Otezla 30 mg twice daily and 23.6 % for placebo. The proportion of patients with an ACR 20 response at Week 16 without concomitant DMARD use was 46.8% for Otezla 30 mg twice daily and 10.3% for placebo. ................
................